MA39995B1 - Composés destinés à traiter l'amyotrophie spinale - Google Patents

Composés destinés à traiter l'amyotrophie spinale

Info

Publication number
MA39995B1
MA39995B1 MA39995A MA39995A MA39995B1 MA 39995 B1 MA39995 B1 MA 39995B1 MA 39995 A MA39995 A MA 39995A MA 39995 A MA39995 A MA 39995A MA 39995 B1 MA39995 B1 MA 39995B1
Authority
MA
Morocco
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
formula
Prior art date
Application number
MA39995A
Other languages
English (en)
Inventor
Luke Green
Hasane Ratni
Nikolai A Naryshkin
Marla L Weetall
Original Assignee
Hoffmann La Roche
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Ptc Therapeutics Inc filed Critical Hoffmann La Roche
Publication of MA39995B1 publication Critical patent/MA39995B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La présente invention concerne des composés représentés par la formule (i) dans laquelle a, r1, r2 et r3 ont la signification indiquée dans la description, ainsi que des sels pharmaceutiquement acceptables de ceux-ci. L'invention concerne également la fabrication des composés représentés par la formule (i), des compositions pharmaceutiques comprenant ces composés, et leur utilisation en tant que médicaments.
MA39995A 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale MA39995B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (fr) 2014-05-15 2015-05-11 Composés pour le traitement d'une amyotrophie spinale

Publications (1)

Publication Number Publication Date
MA39995B1 true MA39995B1 (fr) 2019-11-29

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051988A MA51988A (fr) 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
MA39995A MA39995B1 (fr) 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051988A MA51988A (fr) 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale

Country Status (35)

Country Link
US (1) US9969754B2 (fr)
EP (3) EP4241772A3 (fr)
JP (1) JP6236173B2 (fr)
KR (2) KR102213740B1 (fr)
CN (1) CN106459092B (fr)
AR (1) AR100442A1 (fr)
AU (1) AU2015261046C1 (fr)
CA (1) CA2948561C (fr)
CL (1) CL2016002836A1 (fr)
CR (1) CR20160518A (fr)
DK (1) DK3143025T3 (fr)
EA (2) EA035068B1 (fr)
ES (2) ES2761423T3 (fr)
FR (1) FR21C1039I2 (fr)
HR (2) HRP20230637T1 (fr)
HU (2) HUE046491T2 (fr)
IL (2) IL248653B (fr)
LT (1) LTPA2021010I1 (fr)
MA (2) MA51988A (fr)
MX (1) MX371050B (fr)
MY (1) MY174284A (fr)
NL (1) NL301128I2 (fr)
NO (1) NO2021035I1 (fr)
NZ (1) NZ725008A (fr)
PE (1) PE20170128A1 (fr)
PH (1) PH12016502081A1 (fr)
PL (2) PL3663296T3 (fr)
PT (1) PT3143025T (fr)
RS (1) RS59718B1 (fr)
SG (1) SG11201609497TA (fr)
SI (2) SI3663296T1 (fr)
TW (1) TWI667239B (fr)
UA (1) UA119670C2 (fr)
WO (1) WO2015173181A1 (fr)
ZA (1) ZA201607026B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119916A2 (fr) 2012-02-10 2013-08-15 Ptc Therapeutics, Inc. Composés destinés au traitement de l'amyotrophie spinale
MX2016001963A (es) 2013-08-19 2016-05-26 Hoffmann La Roche Metodo de seleccion.
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
JP6749343B2 (ja) 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物
EP4249472A3 (fr) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
BR112018009281B1 (pt) * 2015-11-12 2023-10-31 F. Hoffmann-La Roche Ag Composições para tratar atrofia muscular espinhal e seu uso
CA2996657A1 (fr) * 2015-11-12 2017-05-18 Kathleen Dorothy MCCARTHY Composes pour le traitement de la sclerose laterale amyotrophique
WO2017097728A1 (fr) 2015-12-10 2017-06-15 F. Hoffmann-La Roche Ag Dérivés de pipéridine pontés
KR102488323B1 (ko) 2015-12-10 2023-01-12 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
MX2019005588A (es) * 2016-11-28 2019-10-15 Ptc Therapeutics Inc Metodos para modular corte y empalme de arn.
MX2019014514A (es) 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
KR20200058468A (ko) * 2017-09-22 2020-05-27 에프. 호프만-라 로슈 아게 7-(4,7-다이아자스피로[2.5]옥탄-7-일)-2-(2,8-다이메틸이미다조[1,2-b]피리다진-6-일)피리도[1,2-a]피리미딘-4-온 유도체의 제조 방법
EP3691647A1 (fr) * 2017-10-03 2020-08-12 H. Hoffnabb-La Roche Ag Nouveau traitement de la sma
WO2019191092A1 (fr) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Composés pour le traitement de la maladie de huntington
KR20210042265A (ko) 2018-06-27 2021-04-19 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물
EP3814360A1 (fr) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
CA3116458C (fr) 2018-10-19 2023-12-12 F. Hoffmann-La Roche Ag Nouvelles formes de derives de pyrido[1,2-a] pyrimidin-4-one, sa formulation et son procede de fabrication
WO2020249577A1 (fr) 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag Nouveau traitement de sma
US20220315607A1 (en) 2019-07-31 2022-10-06 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (fr) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Forme cristalline du risdiplam, son procédé de préparation et son utilisation
WO2022162107A1 (fr) 2021-02-01 2022-08-04 Sandoz Ag Forme cristalline de risdiplam
CN116981673A (zh) * 2021-03-17 2023-10-31 豪夫迈·罗氏有限公司 新颖噻二唑并嘧啶酮衍生物
CA3212341A1 (fr) 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag Nouveaux derives de thiazolopyrimidinone
CN117015546A (zh) 2021-03-18 2023-11-07 豪夫迈·罗氏有限公司 制备利司扑兰的方法
WO2023057404A1 (fr) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Nouvelle administration combinée
WO2023202501A1 (fr) * 2022-04-18 2023-10-26 深圳市塔吉瑞生物医药有限公司 Composé de pyridopyrimidinone substitué, composition le comprenant et son utilisation
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005661A1 (fr) * 1996-08-06 1998-02-12 Pfizer Inc. Derives 6,6- ou 6,7-bicycliques contenant pyrido ou pyrimido substitues
CA2700841A1 (fr) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Composes d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
WO2009151546A2 (fr) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Procédés de traitement d'une atrophie musculaire spinale
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
EP2337609B1 (fr) * 2008-08-14 2016-08-17 Cardiac Pacemakers, Inc. Évaluation et adaptation des performances d'une liaison de communication acoustique
US9617268B2 (en) * 2011-12-30 2017-04-11 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2013119916A2 (fr) * 2012-02-10 2013-08-15 Ptc Therapeutics, Inc. Composés destinés au traitement de l'amyotrophie spinale
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
BR112018009281B1 (pt) 2015-11-12 2023-10-31 F. Hoffmann-La Roche Ag Composições para tratar atrofia muscular espinhal e seu uso

Also Published As

Publication number Publication date
US9969754B2 (en) 2018-05-15
MA51988A (fr) 2021-01-20
WO2015173181A1 (fr) 2015-11-19
EA201692280A1 (ru) 2018-07-31
BR112016026205A2 (pt) 2017-08-15
PH12016502081A1 (en) 2017-01-09
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
NL301128I1 (fr) 2021-09-22
EA035068B1 (ru) 2020-04-23
TWI667239B (zh) 2019-08-01
NZ725008A (en) 2019-11-29
JP6236173B2 (ja) 2017-11-22
IL248653B (en) 2019-11-28
PE20170128A1 (es) 2017-03-16
IL270027B (en) 2020-08-31
NL301128I2 (nl) 2021-10-25
EA202090486A3 (ru) 2020-08-31
KR102213740B1 (ko) 2021-02-09
EP3663296A1 (fr) 2020-06-10
KR20210014219A (ko) 2021-02-08
UA119670C2 (uk) 2019-07-25
NO2021035I1 (no) 2021-09-10
ES2761423T3 (es) 2020-05-19
HUS2100037I1 (hu) 2021-10-28
SI3663296T1 (sl) 2023-08-31
PL3143025T3 (pl) 2020-03-31
CA2948561C (fr) 2019-10-22
ES2949660T3 (es) 2023-10-02
IL248653A0 (en) 2017-01-31
CL2016002836A1 (es) 2017-04-21
CR20160518A (es) 2017-02-21
US20170197990A1 (en) 2017-07-13
AU2015261046A1 (en) 2016-10-27
EP4241772A2 (fr) 2023-09-13
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
PT3143025T (pt) 2019-12-03
CA2948561A1 (fr) 2015-11-19
DK3143025T3 (da) 2019-12-09
EP4241772A3 (fr) 2023-11-15
BR112016026205A8 (pt) 2021-07-20
CN106459092A (zh) 2017-02-22
CN106459092B (zh) 2019-10-15
RS59718B1 (sr) 2020-01-31
AU2015261046B2 (en) 2019-04-18
EP3143025B1 (fr) 2019-10-09
KR20170003687A (ko) 2017-01-09
JP2017515863A (ja) 2017-06-15
AR100442A1 (es) 2016-10-05
EP3663296B1 (fr) 2023-05-17
SG11201609497TA (en) 2016-12-29
AU2015261046C1 (en) 2019-07-25
TW201609738A (zh) 2016-03-16
MY174284A (en) 2020-04-01
HUE046491T2 (hu) 2020-03-30
FR21C1039I1 (fr) 2021-10-15
SI3143025T1 (sl) 2020-01-31
KR102256013B1 (ko) 2021-05-26
LTPA2021010I1 (fr) 2021-10-11
MX2016014547A (es) 2017-02-23
FR21C1039I2 (fr) 2022-09-02
HRP20230637T1 (hr) 2023-09-29
PL3663296T3 (pl) 2023-08-07
EP3143025A1 (fr) 2017-03-22

Similar Documents

Publication Publication Date Title
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
PH12018500061A1 (en) Oxysterols and methods of use thereof
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MA40225A (fr) Composés dihydroisoquinolinone substitués
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
MA40281A (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
EA201890532A1 (ru) Новые аннелированные бензамиды
EA202192433A1 (ru) Соединения, полезные в терапии вич
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
TR201819805T4 (tr) Flavaglin türevleri̇.
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines